Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/1999
08/25/1999CN1226842A Preservation by foam formation
08/25/1999CN1226834A Use of (meth) acrylic acid copolymers to increase permeability of mucous membranes
08/25/1999CN1226833A Remedy for autoimmune diseases
08/25/1999CN1226832A Atrial natriuretic peptide (ANP) as additive to peritoneal dialysis solutions
08/25/1999CN1226829A Method for treating gastrointestinal damage
08/25/1999CN1226827A Amino acid compositions and use thereof in immunosuppression
08/25/1999CN1226425A Lesion-directed antibiotics in dry dosage forms for treatment of shallow ulcers of oral mucosa
08/24/1999US5942550 Cholesterol lowering drink mix compositions
08/24/1999US5942530 Method for treating pain
08/24/1999US5942513 Administering with diuretic suppresses efflux of antagonist through the blood-brain barrier increasing the duration of action and magnitude of effect of antagonist; treatment of stroke, schizophrenia, anxiety; antiepileptic agents
08/24/1999US5942512 Method and composition for treating erectile dysfunction
08/24/1999US5942503 Use of Epinastine for the treatment of pain
08/24/1999US5942500 Dietary composition to reduce dietary fats
08/24/1999US5942497 Purine compound and catecholamine compound containing compositions and methods for administration
08/24/1999US5942405 Identifying compounds which inhibit complement receptors by mixing cells expressing surface complement receptors with a labeled compound capable of binding receptor and determining if compound inhibits interactions by signal generation
08/24/1999US5942400 Assays for detecting β-secretase
08/24/1999US5942250 Compositions and methods for enhancing the topical effects of sunscreen agents
08/24/1999US5942243 Mucoadhesive compositions for administration of biologically active agents to animal tissue
08/24/1999US5942241 A sustained release drug containing a substrate comprising a local anesthetic and a biocompatible, biodegradable, controlled release polymer selected from polyanhydrides, lactic acid and glycolic acid homo-or/and copolymers
08/24/1999US5942225 Comprising the stem cells and one or more bioactive factors for inducing differentiation of them into a single particular lineage, e.g. bone, muscle, tendon, ligament, connective tissue cells
08/24/1999CA2248972A1 Novel compounds
08/24/1999CA2212548C Use of carbazole compounds for the treatment of congestive heart failure
08/20/1999CA2249653A1 Novel compounds
08/19/1999WO1999041411A2 Method for diagnosis and treatment of disorders of carbohydrate metabolism
08/19/1999WO1999041402A2 Targeting of genetic vaccine vectors
08/19/1999WO1999041387A2 Prostate-associated serine protease
08/19/1999WO1999041375A2 Human receptor proteins
08/19/1999WO1999041374A2 Human short-chain tnf-receptor family protein
08/19/1999WO1999041373A2 Human transport-associated molecules
08/19/1999WO1999041369A2 Genetic vaccine vector engineering
08/19/1999WO1999041368A2 Optimization of immunomodulatory properties of genetic vaccines
08/19/1999WO1999041285A1 Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
08/19/1999WO1999041251A1 Antagonists of gonadotropin releasing hormone
08/19/1999WO1999040946A2 Methods and compositions for modulating leptin activity
08/19/1999WO1999040945A2 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
08/19/1999WO1999040917A1 Combination of an alpha-adrenergic antagonist and a nitrogen oxide donor for treating female sexual dysfunction
08/19/1999WO1999040916A1 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
08/19/1999WO1999040909A1 Method for modulating macrophage activation
08/19/1999WO1999040867A1 Treatment of brain edema using carbonic anhydrase enzyme inhibitor
08/19/1999WO1999040788A1 Inotropic and diuretic effects of exendin and glp-1
08/19/1999WO1999032098A3 Combination of a ramba and a tocopherol
08/19/1999WO1999030708A3 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
08/19/1999WO1999030670A3 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
08/19/1999WO1999029662A3 Urethanes, thio and dithio analogues, the salts thereof, medicaments containing said compounds, use and method for the production thereof
08/19/1999WO1999024024A3 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
08/19/1999WO1999023108A9 Inducible phosphofructokinase and the warburg effect
08/19/1999WO1999016419A9 Perforated microparticles and methods of use
08/19/1999WO1998055110A3 NEW USES FOR COMPOUNDS WHICH REDUCE c-jun GENE EXPRESSION
08/19/1999WO1998050074A3 Compositions of antichlamydial agents for the diagnosis and management of infection caused by chlamydia
08/19/1999DE19802377A1 Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs Use of inhibitors for the treatment of RTK function-related disorders, particularly cancer
08/19/1999CA2632106A1 Method for modulating macrophage activation
08/19/1999CA2321136A1 Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
08/19/1999CA2321105A1 Human short-chain tnf-receptor family protein
08/19/1999CA2320960A1 Optimization of immunomodulatory properties of genetic vaccines
08/19/1999CA2320934A1 Treatment of brain edema using carbonic anhydrase inhibitor
08/19/1999CA2320626A1 Genetic vaccine vector engineering
08/19/1999CA2320431A1 Targeting of genetic vaccine vectors
08/19/1999CA2320427A1 Human receptor proteins
08/19/1999CA2320424A1 Human transport-associated molecules
08/19/1999CA2320302A1 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
08/19/1999CA2320226A1 Methods and compositions for modulating leptin activity
08/19/1999CA2319065A1 Method for diagnosis and treatment of disorders of carbohydrate metabolism
08/19/1999CA2317451A1 Antagonists of gonadotropin releasing hormone
08/19/1999CA2312991A1 Prostate-associated serine protease
08/18/1999EP0935963A2 The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
08/18/1999EP0935663A2 Multi-functional chimeric hematopoietic receptor agonists
08/18/1999EP0935655A1 Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
08/18/1999EP0935608A1 Cytotoxic peptides
08/18/1999EP0935471A1 Mononuclear phagocytes in therapeutic drug delivery
08/18/1999EP0935467A1 Compounds that inhibit interaction between signal-transducing proteins and the glgf (pdz/dhr) domain and uses thereof
08/18/1999EP0935466A1 Method and composition for inhibiting cellular irreversible changes due to stress
08/18/1999EP0935462A1 Photopheresis treatment of leukocytes
08/18/1999EP0935457A1 Preparation for the transport of an active substance across barriers
08/18/1999EP0935415A1 Methods for delivering compounds into a cell
08/18/1999EP0799174B1 Biocidal alcohols, their production and their use
08/18/1999EP0792292B1 Orphan receptor
08/18/1999EP0697869B1 Transdermal therapeutic systems for the administration of serotonin agonists
08/18/1999CN1226254A Method and composition useful for inhibition of vasculogenesis of alpha, beta medium
08/18/1999CN1226174A Use of proteinase inhibitors for prevention or reduction of bone resorption
08/18/1999CN1226171A Type-2 chemokine binding proteins and methods of use thereof
08/18/1999CN1226164A Method for treating liver disease and like indications with vasodilating agent
08/18/1999CN1226160A Device for topical treatment of acne and its method of manufacture
08/17/1999US5939540 Platelet secretory transport protein
08/17/1999US5939459 Contacting with an inflammatory mediator selected from the group consisting of pyruvate and a pyruvate precursor and is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant
08/17/1999US5939456 Pulsed administration of compositions for the treatment of blood disorders
08/17/1999US5939455 Augmenting the therapeutic activity of an oxyalkylene-containing compound which comprises administering to a patient or host cells an amount of an inhibitor of .beta.-oxidation of fatty acids; effective to treat or
08/17/1999US5939442 Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
08/17/1999US5939425 Method for treating a migraine
08/17/1999US5939407 Vitamin d receptors for nervous system disorders
08/17/1999US5939391 Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
08/17/1999US5939387 Insulin like growth hormone
08/17/1999US5939321 Mammalian tolloid-like gene and protein
08/17/1999US5939298 Isolated polynucleotide segment having amino acid sequence homology to a known haemophilus influenzae phenylalanyl trna synthetase (alpha-subunit)protein; can be used to screen for antibacterial compounds
08/17/1999US5939284 Protein phosphatase 1 binding protein, R5
08/17/1999US5939271 Recombinant nucleic acid molecule coding for polypeptide which has cell and neuron chemotactic functions; diagnosis, gene therapy, immunogens
08/17/1999US5939095 At least one parasympathomimetically active substance and at least one parasympatholytically active substance
08/17/1999US5939069 Inhibiting the development of insulin dependent diabetes by administering indomethacin or n-2-cyclohexlyoxynitrophenyl methanesulfonamide
08/12/1999WO1999040220A2 Method of screening therapeutic agents
08/12/1999WO1999040201A1 Protein
08/12/1999WO1999040117A1 THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
1 ... 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 ... 1151